Interleukin-2 has known efficacy in the treatment of metastatic renal cell carcinoma but it also has adverse effects mediated by an inflammatory mechanism and capillary leak syndrome. The authors report the case of a patient with a metastatic renal cell carcinoma who had an asymptomatic intra-epidural metastasis in the thoracic spine, which became symptomatic during IL-2 administration without any recurrence after specific treatment by surgery and radiotherapy.
SmithK.A.: Interleukin-2: inception, impact and implications. Science, 240: 1169–1176, 1988.
2.
ChangA.E., RosenbergS.A.: Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol, 5: 385–390, 1989.
3.
FyfeG., FisherR.I., RosenbergS.A., SznolM., ParkinsonD.R., LouieA.C.: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol, 13: 688–696, 1993.
4.
NégrierS., EscudierB., LassetC., DouillardJ.Y., SavaryJ., ChevreauC., RavaudA., MercatelloA., PenyJ., MousseauM., PhilipT., TurszT.: Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med, 338: 1272–1278, 1998.
ButerJ., SleijferD.T., Van der GraafW.T., De VriesE.G., WillemseP.H., MulderN.H.: A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol, 20(6 Suppl 9): 16–21, 1993.
8.
RosensteinM., EttinghausenS.E., RosenbergS.A.: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol, 137: 1735–1742, 1986.
9.
LotzeM.T., MatoryY.L., EttinghausenS.E., RaynerA.A., SharrowS.O., SeippC.A., CusterM.C., RosenbergS.A.: In vivo administration of purified human interleukin 2. Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol, 135: 2865–2875, 1985.
KragelA.H., TravisW.D., SteisR.G., RosenbergS.A., RobertsW.C.: Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer, 66: 1513–1516, 1990.
12.
KragelA.H., TravisW.D., FeinbergL., PittalugaS., StrikerL.M., RobertsW.C., LotzeM.T., YangJ.J., RosenbergS.A.: Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a post-mortem study of 19 patients. Hum Path, 21: 493–502, 1990.
13.
BalunaR., VitettaE.S.: Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology, 37: 117–132, 1997.
14.
DamleN.K., DoyleL.V., BenderJ.R., BradleyE.C.: Interleukin 2-activated human lymphocytes exhibit enhanced adhesion to normal vascular endothelial cells and cause their lysis. J Immunol, 138: 1779–1785, 1987.
15.
CotranR.S., PoberJ.S., GimbroneM.A.Jr., SpringerT.A., WiebkeE.A., GaspariA.A., RosenbergS.A., LotzeM.T.: Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for a vascular leak syndrome. J Immunol, 140: 1883–1888, 1988.
16.
OhkuboC., BigosD., JainR.K.: Interleukin 2 induced leukocyte adhesion to the normal and tumor microvascular endothelium in vivo and its inhibition by dextran sulfate: implications for vascular leak syndrome. Cancer Res, 51: 1561–1563, 1991.
17.
ThijsL.G., HackC.E., Strack van SchijndelR.J., NuijensJ.H., WolbinkG.J., Eerenberg-BelmerA.J., Van der VallH., WagstaffJ.: Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J Immunol, 144: 2419–2424, 1990.
18.
LissoniP., BarniS., CattaneoG., ArchiliC., CrispinoS., TanciniG., D'AngeloL., MagniS., FiorelliG.: Activation of the complement system during immunotherapy of cancer with interleukin-2: a possible explanation of the capillary leak syndrome. Int J Biol Markers, 5: 195–197, 1990.
19.
SarisS.C., PatronasN.J., RosenbergS.A., AlexanderJ.T., FrankJ., SchwartzentruberD.J., RubinJ.T., BarbaD., OldfieldE.H.: The effect of intravenous interleukin-2 on brain water content. J Neurosurg, 71: 169–174, 1989.
